Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Not Yet Opened 01-21 16:00:00 EST

2.56

-0.08

-3.03%

盘后2.51

-0.05-1.95%

19:45 EST

High2.65	Low2.50	Vol35.81K
Open2.58	D1 Closing2.64	Amplitude5.68%
Mkt Cap3.84M	Tradable Cap3.20M	Total Shares1.50M
T/O92.96K	T/O Rate2.87%	Tradable Shares1.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":2.56,"timestamp":1769029200000,"preClose":2.64,"halted":0,"volume":35814,"hourTrading":{"tag":"盘后","latestPrice":2.51,"preClose":2.56,"latestTime":"19:45 EST","volume":2307,"amount":5856.84,"timestamp":1769042708327,"change":-0.05,"changeRate":-0.019531,"amplitude":0.035156},"delay":0,"changeRate":-0.030303030303030328,"floatShares":1248466,"shares":1499796,"eps":-34.23868,"marketStatus":"Not Yet Opened","change":-0.08,"latestTime":"01-21 16:00:00 EST","open":2.58,"high":2.65,"low":2.5,"amount":92955.040023,"amplitude":0.056818,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-34.23868,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769072400000},"marketStatusCode":0,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":2.64,"preHourTrading":{"tag":"盘前","latestPrice":2.57,"preClose":2.64,"latestTime":"09:16 EST","volume":751,"amount":1947.1527717000001,"timestamp":1769004990210,"change":-0.07,"changeRate":-0.026515,"amplitude":0.057955},"postHourTrading":{"tag":"盘后","latestPrice":2.51,"preClose":2.56,"latestTime":"19:45 EST","volume":2307,"amount":5856.84,"timestamp":1769042708327,"change":-0.05,"changeRate":-0.019531,"amplitude":0.035156},"volumeRatio":0.114031},"requestUrl":"/m/hq/s/CMND/tweets","defaultTab":"tweets","newsList":[{"id":"2603698116","title":"Psychedelic: Clearmind completes second cohort treatment for CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2603698116","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603698116?lang=en_us&edition=fundamental","pubTime":"2026-01-15 23:40","pubTimestamp":1768491615,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on treatment completion, real world ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-second-cohort-treatment-for-cmnd-100-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-clearmind-completes-second-cohort-treatment-for-cmnd-100-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2603611416","title":"BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2603611416","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603611416?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:02","pubTimestamp":1768399341,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Inc - Topline Results From Second Cohort Of CMND-100 Expected In Coming MonthsJan 14 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE INC - TOPLINE RESULTS FROM SE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF1UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2603761156","title":"Clearmind Medicine Inc - Topline Results From Second Cohort of Cmnd-100 Expected in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2603761156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603761156?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:55","pubTimestamp":1768398956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF1UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2603115786","title":"Clearmind Medicine Completes Second Cohort Treatment in Phase I/IIa Trial for Alcohol Use Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2603115786","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603115786?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:55","pubTimestamp":1768398914,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, an MEAI-based oral drug candidate for Alcohol Use Disorder . The multinational, multicenter study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The second cohort, consisting of six patients across sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has completed treatment per protocol. Topline results from the second cohort are expected to be presented in the coming months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL8BYjTh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","CMND","SG9999014039.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","BK4007","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2603611650","title":"Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2603611650","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603611650?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:55","pubTimestamp":1768398900,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, Jan.  14, 2026  (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/14/3218685/0/en/Clearmind-Medicine-Announces-Successful-Completion-of-Treatment-in-All-Patients-of-the-Second-Cohort-in-Ongoing-Phase-I-IIa-Clinical-Trial-for-CMND-100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2595770857","title":"Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2595770857","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595770857?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:48","pubTimestamp":1767192481,"startTime":"0","endTime":"0","summary":"Clearmind Medicine  said Wednesday it has received a Nasdaq notice stating it has regained compliance with the exchange's minimum bid price requirement.The notice stated the closing bid price of the company's common shares was at $1 per share or greater for 10 business days from Dec. 15 through Dec. 29, the company said.Price: 1.90, Change: +0.04, Percent Change: +2.20","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NQmain","BK4007","CMND"],"gpt_icon":0},{"id":"2595772114","title":"Clearmind Medicine Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595772114?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:10","pubTimestamp":1767190200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUACG6S1H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2595846797","title":"Clearmind Medicine Reports Positive Phase I/IIa Results for CMND-100 in Alcohol Use Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2595846797","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595846797?lang=en_us&edition=fundamental","pubTime":"2025-12-29 19:04","pubTimestamp":1767006273,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. announced progress in its multinational Phase I/IIa clinical trial evaluating CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound for the treatment of Alcohol Use Disorder. In 2025, the company completed site activations at institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The first-in-human dosing was initiated, and treatment and enrollment for the first cohort were completed, with positive top-line safety and tolerability results reported and no serious adverse events observed. The Data and Safety Monitoring Board unanimously approved the continuation of the trial after an interim review. Enrollment and dosing for the second cohort have also been completed, with further data readouts expected in the future.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL494Qx5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2593500470","title":"Clearmind Medicine Advances Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2593500470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593500470?lang=en_us&edition=fundamental","pubTime":"2025-12-24 22:15","pubTimestamp":1766585716,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. announced significant progress in its multinational Phase I/IIa clinical trial of CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound developed for the treatment of Alcohol Use Disorder . In 2025, the company completed site activations at leading institutions, including Yale School of Medicine and Johns Hopkins University School of Medicine, and successfully initiated first-in-human dosing. Enrollment and dosing for the first two cohorts have been completed, with positive top-line safety and tolerability results reported and no serious adverse events observed. The Data and Safety Monitoring Board  provided unanimous approval to continue the study following an interim review. Additional clinical data readouts are expected as the trial progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDLxB5Vg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014039.USD","CMND","LU0314104364.USD","SG9999014021.USD","LU2210150020.SGD","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"2591185987","title":"Clearmind Medicine Completes Second Cohort Enrollment in Phase I/IIa Trial for Alcohol Use Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591185987","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591185987?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:45","pubTimestamp":1765892732,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced the successful completion of patient enrollment for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, an MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder . The trial, which is being conducted across Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Dosing for the second cohort is expected to begin shortly, with topline results anticipated in the coming months. Results from the first cohort have already been presented, showing a favorable safety profile and preliminary signals of reduced cravings and withdrawal symptoms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1QHD5m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND","SG9999014021.USD","BK4588","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2591987142","title":"Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2591987142","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591987142?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:45","pubTimestamp":1765892700,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, Dec.  16, 2025  (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on the discovery and","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206246/0/en/Clearmind-Medicine-Announces-Successful-Completion-of-Second-Cohort-Enrollment-in-Ongoing-FDA-Approved-Phase-I-IIa-Trial-for-CMND-100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2590036855","title":"Clearmind Medicine Regains Nasdaq Compliance Amid Equity Rule Scrutiny","url":"https://stock-news.laohu8.com/highlight/detail?id=2590036855","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590036855?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:32","pubTimestamp":1765539132,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. recently addressed a regulatory issue related to Nasdaq's Minimum Stockholders' Equity Rule, which requires listed companies to maintain at least $2,500,000 in stockholders' equity. The company received notification from Nasdaq confirming it had regained compliance with this rule. However, Nasdaq will continue to monitor Clearmind Medicine's compliance, and failure to meet the requirement in future periodic reports could result in delisting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire  on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL50pZXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B64PRP62.GBP","BK4007","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210149790.SGD","BK4585","LU2095319765.USD","NDAQ","LU2210150020.SGD","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","LU0314104364.USD","CMND"],"gpt_icon":0},{"id":"2590503524","title":"Clearmind Medicine Successfully Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503524","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503524?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:32","pubTimestamp":1765539120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA99RGQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2590558058","title":"Clearmind Medicine Announces 1-for-40 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558058","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558058?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:15","pubTimestamp":1765401312,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced a 1-for-40 reverse share split of its common shares, effective December 15, 2025. This move aims to help the company regain compliance with Nasdaq's minimum bid price requirement. After the reverse split, the number of outstanding common shares will be reduced from approximately 60 million to about 1.5 million, with fractional shares rounded up to the nearest whole share. The company's authorized share capital remains unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire  on December 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL9JFRzG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B64PRP62.GBP","BK4007","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210149790.SGD","BK4585","LU2095319765.USD","NDAQ","LU2210150020.SGD","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","LU0314104364.USD","CMND"],"gpt_icon":0},{"id":"2589488058","title":"Clearmind Medicine Faces Nasdaq Delisting Risk Over Sub-$1 Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2589488058","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589488058?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:00","pubTimestamp":1764972011,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has received notice from the Nasdaq Stock Market that it is not in compliance with the minimum bid price requirement, as its common shares have traded below $1.00 for 30 consecutive business days. The company has until June 2, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Failure to meet this requirement could result in the delisting of its shares from Nasdaq. The company is evaluating its options to address the issue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire  on December 05, 2025, and is solely responsible for the information containe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL6mNrQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","BK4007","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","CMND","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588469090","title":"BRIEF-Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588469090","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588469090?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:51","pubTimestamp":1764766261,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Inc Files For Offering Of Up To 16 Million Common Shares - SEC FilingDec 3  - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE INC FILES FOR OFFERING OF UP TO 16 MILLION COMMON SHARES - SEC FILINGSource text: [ID:n0001213900-25-117534]Further company coverage: CMND.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X815M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2588056135","title":"BRIEF-Clearmind Medicine Advances Cmnd-100 To Dosing Phase At Hadassah Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056135?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:57","pubTimestamp":1764683859,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Advances Cmnd-100 To Dosing Phase At Hadassah Medical CenterDec 2 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE ADVANCES CMND-100 TO DOSING PHASE AT HADASSAH ME","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4F7YPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2588053511","title":"Clearmind Medicine Advances Cmnd-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/Iia Clinical Trial for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053511?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:57","pubTimestamp":1764680235,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA4F7YPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2588847773","title":"Clearmind Medicine Reports Positive Early Results in Phase I/IIa Trial for Alcohol Use Disorder Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588847773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588847773?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:56","pubTimestamp":1764597376,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary, non-hallucinogenic, MEAI-based oral therapy developed for Alcohol Use Disorder . The company reported positive top-line safety and efficacy results from the trial's first cohort of six participants, with dosing conducted at Johns Hopkins University School of Medicine and Yale School of Medicine. Following an unblinded interim safety review, the independent Data and Safety Monitoring Board  unanimously recommended that the trial proceed. Additionally, Clearmind has expanded its clinical network by initiating patient enrollment at Tel Aviv Sourasky Medical Center in Israel, joining other active sites in the multinational study. Results from the initial cohort have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL28dVVq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","CMND","BK4007","IE00B64PRP62.GBP","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2588738487","title":"Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full Dsmb Approval, and New Elite Site Joins the Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588738487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588738487?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:56","pubTimestamp":1764597360,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA7YZXQ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":0.0449},{"period":"1month","weight":-0.0116},{"period":"3month","weight":-0.9348},{"period":"6month","weight":-0.9379},{"period":"1year","weight":-0.9556},{"period":"ytd","weight":0.4144}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.013252},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.046234},{"month":3,"riseRate":0,"avgChangeRate":-0.347646},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.169588},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.01702},{"month":6,"riseRate":0.333333,"avgChangeRate":0.080414},{"month":7,"riseRate":0.333333,"avgChangeRate":0.008507},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.088917},{"month":9,"riseRate":0,"avgChangeRate":-0.22938},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}